Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia

Gastroenterology Report

Volumn 3, Issue 4, 2015, Pages 344-349

  Horvath, Bela ^a   Liu, Ganglei ^a,b   Wu, Xianrui ^c   Lai, Keith K ^d   Shen, Bo ^a   Liu, Xiuli ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Colorectal neoplasia; Crohn's disease; Cytokeratin 7; Inflammatory bowel disease; P53; Ulcerative colitis

Indexed keywords

EID: 84992220463     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gov022     Document Type: Article

References (24)

1. Rosenqvist H, Ohrling H, Lagercrantz R et al. Ulcerative colitis and carcinoma coli. Lancet 1959;1:906-8.
2. Ekbom A, Helmick C, Zack M et al. Increased risk of largebowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-9.
3. Jess T, Winther KV, Munkholm P et al. Intestinal and extra-intestinal cancer in Crohn's disease: Follow-up of a populationbased cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19:287-93.
4. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: A meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100: 2724-9.
5. Breynaert C, Vermeire S, Rutgeerts P, et al. Dysplasia and colorectal cancer in inflammatory bowel disease: A result of inflammation or an intrinsic risk? Acta Gastroenterol Belg 2008; 71:367-72.
6. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983;14: 931-68.
7. Zisman TL, Bronner MP, Rulyak S et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis during current cancer surveillance guidelines. Inflamm Bowel Dis 2012;18:2240-6.
8. Pekow JR, Hetzel JT, Rothe JA et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis 2010;16:1352-6.
9. Venkatesh PG, Jegadeesan R, Gutierrez NG et al. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2013;7: 968-73.
10. Ullman TA, Loftus EV, Jr., Kakar S et al. The fate of lowgradedysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922-7.
11. Ullman T, Croog V, Harpaz N et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-19.
12. Lim CH, Dixon MF, Vail A, et al. Ten-year follow-up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003;52:1127-32.
13. Van Schaik FD, Ten Kate FJ, Offerhaus JA et al. Misclassification of dysplasia in patients with inflammatory bowel disease: Consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis 2011;17:1108-16.
14. Lai KK, Horvath B, Xie H et al. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis 2015;21:378-84.
15. Odze RD, Goldblum JR, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002;15:379-86.
16. Odze RD, Tomaszewski JE, Furth EE et al. Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep 2006;16:1123-9.
17. Xie H, Xiao SY, Pai R et al. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol 2014;27:303-13.
18. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bioinformatics tool for biomarker assessment and outcomebased cut-point optimization. Clin Cancer Res 2004;10:7252-9.
19. Klump B, Holzmann K, Kühn A et al. Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:789-94.
20. Lashner BA, Shapiro BD, Husain A et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 1999;94: 456-62.
21. Nathanson JW, Yadron NE, Farnan J et al. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci 2008;53:474-80.
22. Van Schaik FD, Oldenburg B, Offerhaus GJ et al. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm Bowel Dis 2012;18:480-8.
23. Stenling R, Lindberg J, Rutegard J et al. Altered expression of CK7 and CK20 in preneoplastic and neoplastic lesions in ulcerative colitis. APMIS 2007;115:1219-26.
24. Hussain SP, Amstad P, Raja K et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res 2000; 60:3333-7.